Tributyrin Prodrug Selective Gut Microbiome Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prebiotic and probiotic strategies face challenges in selectively enhancing Bifidobacteria in the gut microbiome, as they often stimulate various bacterial species indiscriminately, lead to gastrointestinal issues, and have poor colonization rates, with existing forms of butyric acid being unstable and odorously unpleasant.
Innovation Solution
Tributyrin-containing compositions, including tributyrin and its derivatives, are administered to selectively increase Bifidobacteria levels, combined with odor-masking components and probiotic microorganisms like Lactobacillus and Bifidobacterium species, in various dosage forms to enhance gut health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If prebiotics are administered to increase proliferation of gut microflora, then bacterial growth is stimulated, but growth is stimulated indiscriminately across various bacterial species rather than selectively enhancing desirable species
Solution Approach 1:
The patent changes the chemical parameter from free butyric acid to tributyrin (a triglyceride ester of butyric acid), which alters the release profile and selectivity of butyrate delivery to specific bacterial species, thereby achieving selective enhancement of desirable gut microflora
Solution Approach 2:
The patent delivers butyrate locally to specific bacterial populations in the colon through the tributyrin prodrug, which is hydrolyzed by specific esterases present in the colon, providing localized and selective stimulation of desirable bacterial species rather than uniform stimulation throughout the gastrointestinal tract
2Quantity of substance
If concentrated butyric acid is administered to reach the colon, then butyric acid availability is increased, but rapid absorption in the upper gastrointestinal tract prevents it from reaching the colon effectively
Solution Approach 1:
The patent uses tributyrin as a prodrug that is stable during storage and administration, and is only hydrolyzed to release butyric acid at the target site (colon) after ingestion, thereby preliminarily protecting the butyric acid from premature absorption in the upper GI tract
Solution Approach 2:
The patent introduces tributyrin as an intermediary compound that serves as a carrier for butyric acid, allowing it to bypass rapid absorption in the upper gastrointestinal tract and reach the colon where it is hydrolyzed to release the active butyric acid
3Stability of the object's composition
If sodium butyrate is administered as a stable solid form, then stability and deliverability are improved, but significant portion is metabolized in the small intestine decreasing overall yield
Solution Approach 1:
The patent changes the chemical form from sodium butyrate salt to tributyrin ester, which has different metabolic properties and is not significantly metabolized in the small intestine, thereby maintaining stability while improving overall yield to the colon
Solution Approach 2:
The patent uses tributyrin as an intermediary that bypasses small intestine metabolism, allowing butyric acid to reach the colon in higher quantities compared to direct administration of sodium butyrate
4Ease of manufacture
If probiotic strains are ingested in freeze-dried form, then probiotic delivery is simplified, but colonization rates in the colon remain poor
Solution Approach 1:
The patent converts the harmful effect of commensal species outcompeting probiotics into a benefit by using tributyrin to selectively stimulate the growth of desirable bacteria including probiotics, thereby turning the competitive environment to the advantage of the probiotic strains
Solution Approach 2:
The patent changes the chemical environment in the colon by delivering tributyrin, which is hydrolyzed to butyric acid, creating favorable conditions for probiotic colonization and counteracting the competitive pressure from commensal species
5Quantity of substance
If butyric acid or sodium butyrate is administered, then butyric acid delivery is achieved, but foul odor makes voluntary consumption and marketing difficult
Solution Approach 1:
The patent changes the physical and sensory parameters of butyric acid delivery by converting it to tributyrin, which has a more pleasant odor and taste profile, thereby improving consumer acceptance and voluntary consumption while maintaining effective butyric acid delivery to the colon
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tributyrin compositions significantly increase Bifidobacteria abundance by up to 8841% and Faecalibacterium by 29%, providing symptomatic relief for conditions like irritable bowel syndrome and Crohn's disease, while improving the Firmicutes to Bacteroidetes ratio for enhanced nutrient absorption.
Implementation Method 1
Tributyrin is a triglyceride and a butyrate ester... tributyrin is hydrolyzed by esterases present in the colon to release butyric acid
Implementation Method 2
Bifidobacteria... metabolize tributyrin and butyric acid... fermentative degradation of the prebiotic may lead to significant gastrointestinal upset
Data Source
AI summary
Tributyrin and/or tributyrin derivatives are used to selectively increase the levels of Bifidobacteria in the gut. In preferred methods, the tributyrin and/or tributyrin derivatives are orally administered alone or in combination with a food item or other nutritionally acceptable carrier, and may further include Bifidobacteria. Tributyrin-enhanced Bifidobacterium strains are also contemplated that include Bifidobacteria previously cultured in tributyrin and/or tributyrin derivatives.